다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
The Canadian journal of cardiology, v.36 no.1, 2020년, pp.127 - 134
Bernelli, Chiara (Interventional Cardiology Unit, Ospedale Santa Corona) , Danzi, Gian Battista (Interventional Cardiology Unit, Ospedale Santa Corona) , Cerrato, Enrico (Interventional Cardiology Unit, San Luigi Gonzaga University Hospital, Orbassano and Rivoli degli Infermi Hospital) , Pierini, Simona (Interventional Cardiology Unit ASST Nord-Milano, Ospedale Bassini) , Ornaghi, Maurizio Giovanni (Interventional Cardiology Unit ASST Nord-Milano, Ospedale Bassini) , Botta, Luca (Cardiac surgery Unit, ASST Grande Ospedale Metropolitano Niguarda, Piazza dell'Ospedale Maggiore) , Gentile, Francesco (Interventional Cardiology Unit ASST Nord-Milano, Ospedale Bassini) , Migliorino, Guglielmo Marco (Infectious Diseases Unit, Azienda Socio-Sanitaria Territoriale di MONZA, San Gerardo Hospital-University of Milano-Bicocca) , Squillace, Nicola (Infectious Diseases Unit, Azienda Socio-Sanitaria Territoriale di MONZA, San Gerardo Hospital-University of Milano-Bicocca Italy<)
AI-Helper
Abstract The introduction of combination of antiretroviral therapy and advancement in care of HIV have dramatically changed the natural history of patients living with HIV. Today, HIV+ patients have a life expectancy not significantly different from HIV uninfected people. However, concerns remain a...
Résumé La combinaison du traitement antirétroviral et de l’amélioration des soins du VIH a changé de façon spectaculaire l’évolution naturelle de l’état de santé des patients vivant avec le VIH. Aujourd’hui, l’espérance de vie des patients séropositifs pour le VIH n’est pas significativement différente de celle des personnes non infectées par le VIH. Cependant, des préoccupations demeurent quant à toutes les affections concomitantes associées au vieillissement et aux effets des traitements de longue durée chez ces patients à risque élevé. Les sujets séropositifs pour le VIH présentent une accélération de l’athérosclérose et un risque entre 1,5 et 2,0 fois plus élevé de maladie coronarienne (MC), qui survient généralement de façon précoce et virulente avec des événements coronariens aigus. De plus, les patients porteurs du VIH qui sont atteints de MC se plaignent souvent d’événements coronariens récurrents et ils subissent des manifestations cardiaques indésirables majeures. Cette revue portera principalement sur les connaissances actuelles relatives au phénotype de la MC chez les patients séropositifs pour le VIH, en portant une attention particulière à la récurrence des événements coronariens aigus et en soulignant le rôle des stratégies de prise en charge percutanée basée sur l’information fournie par l’imagerie coronarienne invasive.
Am J Cardiol Feinstein 117 214 2016 10.1016/j.amjcard.2015.10.030 Patterns of cardiovascular mortality for HIV-infected adults in the United States: 1999 to 2013
Lancet HIV Ryom 5 e291 2018 10.1016/S2352-3018(18)30043-2 Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study
Int J Biochem Cell Biol Bussolino 33 371 2001 10.1016/S1357-2725(01)00024-3 Interactions between endothelial cells and HIV-1
Can J Cardiol Hsue 35 238 2019 10.1016/j.cjca.2018.12.024 Mechanisms of cardiovascular disease in the setting of HIV infection
Can J Cardiol Waters 35 249 2019 10.1016/j.cjca.2018.11.005 Lipid abnormalities in persons living with HIV infection
Heart Hulten 95 1826 2009 10.1136/hrt.2009.177774 HIV positivity, protease inhibitor exposure and subclinical atherosclerosis: a systematic review and meta-analysis of observational studies
Atherosclerosis D’Ascenzo 240 197 2015 10.1016/j.atherosclerosis.2015.03.019 High prevalence at computed coronary tomography of non-calcified plaques in asymptomatic HIV patients treated with HAART: a meta-analysis
JACC Cardiovasc Imaging Stein 7 515 2014 10.1016/j.jcmg.2013.08.019 Arterial disease in patients with human immunodeficiency virus infection: what has imaging taught us?
Circulation Feinstein 9 e98 2019 Characteristics, prevention, and management of cardiovascular disease in people living with HIV: a scientific statement from the American Heart Association
Can J Cardiol Sinha 35 270 2019 10.1016/j.cjca.2018.11.029 Coronary artery disease manifestations in HIV: what, how, and why
J Am Coll Cardiol Boccara 61 511 2013 10.1016/j.jacc.2012.06.063 HIV and coronary heart disease: time for a better understanding
Circulation Hsue 109 316 2004 10.1161/01.CIR.0000114520.38748.AA Clinical features of acute coronary syndromes in patients with human immunodeficiency virus infection
Clin Infect Dis Klein 60 1278 2015 10.1093/cid/civ014 Declining relative risk for myocardial infarction among HIV-positive compared with HIV-negative individuals with access to care
Lancet HIV Rasmussen 2 e288 2015 10.1016/S2352-3018(15)00077-6 Time trends for risk of severe age-related diseases in individuals with and without HIV infection in Denmark: a nationwide population-based cohort study
Can J Cardiol Giguere 35 326 2019 10.1016/j.cjca.2018.12.020 Getting to the heart of the matter: a review of drug interactions between HIV antiretrovirals and cardiology medications
Cardiovasc Pathol Fishbein 17 117 2008 10.1016/j.carpath.2007.07.002 Atherosclerotic oxalosis in coronary arteries
Lancet Tabib 340 730 1992 10.1016/0140-6736(92)92270-P Coronary lesions in young HIV-positive subjects at necropsy
EuroIntervention Theodoropoulos 12 1757 2017 10.4244/EIJ-D-15-00409 Quantitative angiographic characterisation of coronary artery disease in patients with human immunodeficiency virus (HIV) infection undergoing percutaneous coronary intervention
Open Heart O'Dwyer 3 2016 10.1136/openhrt-2016-000511 Lower coronary plaque burden in patients with HIV presenting with acute coronary syndrome
Eur Heart J Gili 37 3600 2016 10.1093/eurheartj/ehv734 Comparative safety and efficacy of statins for primary prevention in human immunodeficiency virus-positive patients: a systematic review and meta-analysis
Thromb Res D’Ascenzo 134 558 2014 10.1016/j.thromres.2014.05.037 Prognostic indicators for recurrent thrombotic events in HIV-infected patients with acute coronary syndromes: use of registry data from 12 sites in Europe, South Africa and the United States
Am J Cardiol Ren 104 216 2009 10.1016/j.amjcard.2009.03.036 Comparison of outcomes using bare metal versus drug-eluting stents in coronary artery disease patients with and without human immunodeficiency virus infection
Circulation Lorgis 127 1767 2013 10.1161/CIRCULATIONAHA.113.001874 Outcomes after acute myocardial infarction in HIV-infected patients: analysis of data from a French nationwide hospital medical information database
Heart Boccara 92 543 2006 10.1136/hrt.2005.068445 Percutaneous coronary intervention in HIV infected patients: immediate results and long term prognosis
Curr HIV Res Boccara 6 59 2008 10.2174/157016208783571900 Coronary artery bypass graft in HIV-infected patients: a multicenter case control study
BMC Cardiovasc Disord Bundhun 17 190 2017 10.1186/s12872-017-0624-0 Does infection with human immunodeficiency virus have any impact on the cardiovascular outcomes following percutaneous coronary intervention?: a systematic review and meta-analysis
J Cardiovasc Med (Hagerstown) Peyracchia 20 321 2019 10.2459/JCM.0000000000000767 In-hospital and long-term outcomes of HIV-positive patients undergoing PCI according to kind of stent: a meta-analysis
J Interv Cardiol Singh 30 405 2017 10.1111/joic.12433 Coronary revascularization for acute myocardial infarction in the HIV population
Eur Heart J Boccara 32 41 2011 10.1093/eurheartj/ehq372 Acute coronary syndrome in human immunodeficiency virus-infected patients: characteristics and 1-year prognosis
Can J Cardiol Yanagawa 35 320 2019 10.1016/j.cjca.2018.11.006 Cardiac surgery in HIV patients: state of the art
Eur Heart J D’Ascenzo 33 875 2012 10.1093/eurheartj/ehr456 Acute coronary syndromes in human immunodeficiency virus patients: a meta-analysis investigating adverse event rates and the role of antiretroviral therapy
J Infect Dis Hatano 208 50 2013 10.1093/infdis/jis630 Cell-based measures of viral persistence are associated with immune activation and programmed cell death protein 1 (PD-1)-expressing CD4+ T cells
Eur Heart J Hauguel-Moreau 38 1676 2017 Platelet reactivity in human immunodeficiency virus infected patients on dual antiplatelet therapy for an acute coronary syndrome: the EVERE2ST-HIV study
N Engl J Med Friis-Møller 356 1723 2007 10.1056/NEJMoa062744 Class of antiretroviral drugs and the risk of myocardial infarction
AIDS Sabin 32 79 2018 10.1097/QAD.0000000000001666 Abacavir use and risk of recurrent myocardial infarction
Atherosclerosis Peyracchia 274 218 2018 10.1016/j.atherosclerosis.2018.05.001 Evaluation of coronary features of HIV patients presenting with ACS: the CUORE, a multicenter study
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.